Elypta is developing the first liquid biopsy platform based on cancer metabolism.
Elypta has raised €27M across 3 funding rounds from 9 investors, most recently a round in Apr 2023. Based in Stockholm, Sweden; founded 2017; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2023-04-04 | Other | €889k | The Roddenberry Foundation | View deal → |
| 2022-06-20 | Series A | €20M | Bonnier Ventures,Chalmers Ventures,Hillclimber,Industrifonden,Navigare Ventures,Nina Capital+1 more | View deal → |
| 2020-01-23 | Seed | €6.0M | Industrifonden,Sciety | View deal → |
